Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019
Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019'; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
The report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 6 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Diffuse Large B-Cell Lymphoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Small-Cell Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Chondrosarcoma, Chordoma, Endometrial Cancer, Epithelial Tumor, Glioblastoma Multiforme (GBM), Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, T-Cell Leukemia, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified, Uterine Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
SCOPE
SUMMARY
According to the recently published report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019'; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.
The report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 6 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Diffuse Large B-Cell Lymphoma, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Follicular Lymphoma, Multiple Myeloma (Kahler Disease), Small-Cell Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Breast Cancer, Central Nervous System (CNS) Tumor, Chondrosarcoma, Chordoma, Endometrial Cancer, Epithelial Tumor, Glioblastoma Multiforme (GBM), Hematological Tumor, Hepatocellular Carcinoma, Leukemia, Lung Cancer, Malignant Mesothelioma, Melanoma, Metastatic Liver Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Tumor, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, T-Cell Leukemia, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified, Uterine Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
- The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
Constellation Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Domainex Ltd
Epizyme Inc
Eternity Bioscience Inc
GlaxoSmithKline Plc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kainos Medicine Inc
OncoFusion Therapeutics Inc
Pfizer Inc
Transgene Biotek Ltd
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
CPI-0209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-169 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBI-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISEZH-22.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JQEZ-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-1943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06821497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH1 and EZH2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazemetostat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBL-0404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valemetostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
Featured News & Press Releases
Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma
Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat
Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma
Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL
Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options
Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma
Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemetostat at American Society of Hematology (ASH)
Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma
Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise
Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat
Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data
Jun 12, 2019: Constellation Pharmaceuticals presentation highlights enhanced EZH2 target engagement, leading to second-generation EZH2 inhibitor CPI-0209
Jun 03, 2019: Epizyme reports updated data from Phase 2 trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
Constellation Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Domainex Ltd
Epizyme Inc
Eternity Bioscience Inc
GlaxoSmithKline Plc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kainos Medicine Inc
OncoFusion Therapeutics Inc
Pfizer Inc
Transgene Biotek Ltd
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
CPI-0209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-169 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBI-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISEZH-22.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JQEZ-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-1943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06821497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH1 and EZH2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazemetostat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBL-0404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valemetostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
Featured News & Press Releases
Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma
Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat
Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unanimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma
Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL
Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options
Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma
Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemetostat at American Society of Hematology (ASH)
Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma
Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise
Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat
Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data
Jun 12, 2019: Constellation Pharmaceuticals presentation highlights enhanced EZH2 target engagement, leading to second-generation EZH2 inhibitor CPI-0209
Jun 03, 2019: Epizyme reports updated data from Phase 2 trial of Tazemetostat for Epithelioid Sarcoma at 2019 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Constellation Pharmaceuticals Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Domainex Ltd, H2 2019
Pipeline by Epizyme Inc, H2 2019
Pipeline by Eternity Bioscience Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Kainos Medicine Inc, H2 2019
Pipeline by OncoFusion Therapeutics Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Transgene Biotek Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Constellation Pharmaceuticals Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Domainex Ltd, H2 2019
Pipeline by Epizyme Inc, H2 2019
Pipeline by Eternity Bioscience Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Kainos Medicine Inc, H2 2019
Pipeline by OncoFusion Therapeutics Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Transgene Biotek Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Constellation Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Domainex Ltd
Epizyme Inc
Eternity Bioscience Inc
GlaxoSmithKline Plc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kainos Medicine Inc
OncoFusion Therapeutics Inc
Pfizer Inc
Transgene Biotek Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Constellation Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Domainex Ltd
Epizyme Inc
Eternity Bioscience Inc
GlaxoSmithKline Plc
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kainos Medicine Inc
OncoFusion Therapeutics Inc
Pfizer Inc
Transgene Biotek Ltd
